[go: up one dir, main page]

WO2006067198A3 - Nouvelles entites biologiques et utilisation ciblee de celles-ci - Google Patents

Nouvelles entites biologiques et utilisation ciblee de celles-ci Download PDF

Info

Publication number
WO2006067198A3
WO2006067198A3 PCT/EP2005/057061 EP2005057061W WO2006067198A3 WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3 EP 2005057061 W EP2005057061 W EP 2005057061W WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted use
engineered enzymes
disease
defined specificity
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/057061
Other languages
English (en)
Other versions
WO2006067198A2 (fr
Inventor
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Direvo Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direvo Biotech AG filed Critical Direvo Biotech AG
Priority to EP05823713A priority Critical patent/EP1827486A2/fr
Publication of WO2006067198A2 publication Critical patent/WO2006067198A2/fr
Publication of WO2006067198A3 publication Critical patent/WO2006067198A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode pour traiter une maladie. Cette méthode consiste à appliquer un médicament comprenant une protéase qui présente une spécificité définie, capable d'hydrolyser des liaisons peptidiques spécifiques à l'intérieur d'un substrat cible lié à ladite maladie. Les protéases présentant une telle spécificité définie peuvent également être utilisées à des fins thérapeutiques ou diagnostiques liées.
PCT/EP2005/057061 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci Ceased WO2006067198A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823713A EP1827486A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106903.0 2004-12-22
EP04106903 2004-12-22

Publications (2)

Publication Number Publication Date
WO2006067198A2 WO2006067198A2 (fr) 2006-06-29
WO2006067198A3 true WO2006067198A3 (fr) 2007-01-04

Family

ID=36602119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/057061 Ceased WO2006067198A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Country Status (2)

Country Link
EP (1) EP1827486A2 (fr)
WO (1) WO2006067198A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
ES2374560T3 (es) 2004-04-12 2012-02-17 Catalyst Biosciences, Inc. Escisión de vegf y receptor de vegf mediante mt-sp1 de tipo silvestre y mutante.
SI1940457T1 (sl) 2005-10-21 2013-04-30 Catalyst Biosciences, Inc. Modificirane proteaze, ki inhibirajo komplementno aktivacijo
NZ596269A (en) 2006-07-05 2012-12-21 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
US9012186B2 (en) 2009-04-27 2015-04-21 The Board Of Trustees Of The University Of Illinois Hemicellulose-degrading enzymes
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
ES2754271T3 (es) * 2013-12-17 2020-04-16 Novo Nordisk As Polipéptidos escindibles por enteroquinasa
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PL3388075T3 (pl) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
CA3118924A1 (fr) 2018-11-09 2020-05-14 Ginkgo Bioworks, Inc. Biosynthese de mogrosides
CA3185040A1 (fr) 2020-05-26 2021-12-02 Truebinding, Inc. Methodes de traitement de maladies inflammatoires par blocage de la galectine-3
CN120230734B (zh) * 2025-06-03 2025-07-29 山东三元生物科技股份有限公司 蔗糖磷酸化酶突变体及其在合成2-O-α-D-吡喃葡萄糖基-L-抗坏血酸中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (fr) * 2002-05-10 2003-11-20 Direvo Biotech Ag Procede de production de proteases a sequences specifiques par evolution dirigee et utilisation de celles-ci
WO2004067737A2 (fr) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (fr) * 2003-06-18 2004-12-29 Direvo Biotech Ag Nouvelles entites biologiques et leur utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (fr) * 2002-05-10 2003-11-20 Direvo Biotech Ag Procede de production de proteases a sequences specifiques par evolution dirigee et utilisation de celles-ci
WO2004067737A2 (fr) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (fr) * 2003-06-18 2004-12-29 Direvo Biotech Ag Nouvelles entites biologiques et leur utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTAMIRANO M M ET AL: "Directed evolution of new catalytic activity using the alpha/beta-barrel scaffold", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 403, no. 6770, 10 February 2000 (2000-02-10), pages 617 - 622, XP002173865, ISSN: 0028-0836 *
COOMBS G.S.: "Directing sequence-specific proteolysis to new targets.", J BIOL. CHEM., vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4323 - 4328, XP002401171 *
HEDSTROM E ET AL: "CONVERTING TRYPSIN TO CHYMOTRYPSIN: THE ROLE OF SURFACE LOOPS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 255, no. 5049, 6 March 1992 (1992-03-06), pages 1249 - 1253, XP001179164, ISSN: 0036-8075 *
KURTH T ET AL: "Engineering the S1' subsite of trypsin: design of a protease which cleaves between dibasic residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, 18 August 1998 (1998-08-18), pages 11434 - 11440, XP002218040, ISSN: 0006-2960 *
SICES H J AND KRISTIE T M: "A genetic screen for the isolation of site-specific proteases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, March 1998 (1998-03-01), pages 2828 - 2833, XP002306297, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Also Published As

Publication number Publication date
WO2006067198A2 (fr) 2006-06-29
EP1827486A2 (fr) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006067198A3 (fr) Nouvelles entites biologiques et utilisation ciblee de celles-ci
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
WO2009093119A3 (fr) Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau
MXPA05003493A (es) Metodos para generar y seleccionar proteasas con especificidad alterada.
EP2175834B8 (fr) Formulation de protéine de fusion glp-1-fc
WO2007081516A3 (fr) Promedicaments specifiques a des tissus
WO2007016476A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
WO2007117482A3 (fr) Inhibiteurs de la rénine
WO2005118634A3 (fr) Composes peptidomimetiques helicoidaux a activite amelioree
WO2004065423A3 (fr) Molecules de reconnaissance pour le traitement et la detection de tumeurs
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2004010937A3 (fr) Methode de traitement du cancer
WO2007117557A3 (fr) Diaminopropanols inhibiteurs de rénine
WO2005120476A3 (fr) Nouvelle utilisation de composes peptidiques pour le traitement de la sclerose laterale amyotrophique
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
WO2008145842A3 (fr) Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
WO2007121124A3 (fr) Composés organiques et leurs utilisations
MX2007008065A (es) Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
WO2007117559A3 (fr) Inhibiteurs de la rénine
WO2009001743A1 (fr) Nouveau mutant adamts-13
WO2007099348A3 (fr) Peptide et ses utilisations
WO2009132149A3 (fr) Traitement des affections liées à un choc septique consécutif à une ligature cæcale
WO2003095475A8 (fr) Composes peptidiques et leur utilisation comme substrats de proteases
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
WO2006023866A3 (fr) Acides thiazolo-naphthyliques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005823713

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005823713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005823713

Country of ref document: EP